Who is sponsoring Apricity-B?

Apricity-B is sponsored by Epion Therapeutics.

What condition does Apricity-B study?

Apricity-B studies Keratoconus.

What drugs are being tested in Apricity-B?

Interventions: Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment.

What is the status of Apricity-B?

Apricity-B is currently ACTIVE_NOT_RECRUITING.

Last reviewed 2025-02-18 · How we verify

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age with Keratoconus (APRICITY-B) (Apricity-B)

NCT06100952 Phase 3 ACTIVE_NOT_RECRUITING

A Multicenter, Randomized, Double-Masked, Sham-Controlled, Parallel-Group Phase 3 Study to Evaluate the Efficacy and Safety of Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

Details

Lead sponsor	Epion Therapeutics
Phase	Phase 3
Status	ACTIVE_NOT_RECRUITING
Enrolment	400
Start date	2023-11-01
Completion	2025-11

Conditions

Keratoconus

Interventions

Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment
Placebo and sham treatment

Primary outcomes

Best Spectacle-Corrected Distance Visual Acuity (BSCDVA) — Baseline to 12 months
BSCDVA will be assessed using Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity testing charts. The score ranges from 0 to 100, with a higher score representing better visual functioning.

Countries

United States